PL EN


Preferences help
enabled [disable] Abstract
Number of results
2014 | 12 | 1 | 31-42
Article title

Rekomendacje Polskiego Towarzystwa Ginekologii Onkologicznej dotyczące diagnostyki i leczenia raka piersi u kobiet ciężarnych

Authors
Content
Title variants
EN
Recommendations of the Polish Gynecological Oncology Society on the diagnosis and treatment of breast cancer during pregnancy
Languages of publication
EN
Abstracts
Keywords
Discipline
Publisher

Year
Volume
12
Issue
1
Pages
31-42
Physical description
Contributors
author
  • I Katedra Chirurgii Uniwersytetu Jagiellońskiego, Collegium Medicum. Kierownik: prof. dr hab. n. med. Jan Kulig Oddział Kliniczny Ginekologii i Onkologii, Szpital Uniwersytecki w Krakowie. Kierownik: prof. dr hab. n. med. Antoni Basta. Dr n. med. Paweł Basta, Oddział Kliniczny Ginekologii i Onkologii, Szpital Uniwersytecki w Krakowie, ul. Kopernika 23, 31-501 Kraków, tel.: +48 12 424 85 84, pbasta@cm-uj.krakow.pl
References
  • 1. Pentheroudakis G., Orecchia R., Hoekstra H.J. i wsp.: Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010; 21: 266–273.
  • 2. Murphy C., Mallam D., Stein S. i wsp.: Current or recent pregnancy is associated with adverse pathologic features but not impaired survival in early breast cancer. Cancer 2012; 118: 3254–3259.
  • 3. Stensheim H., Møller B., van Dijk T. i wsp.: Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J. Clin. Oncol. 2009; 27: 45–51.
  • 4. Beadle B.M., Woodward W.A., Middleton L.P. i wsp.: The impact of pregnancy on breast cancer outcomes in women ≤35 years. Cancer 2009; 115: 1174–1184.
  • 5. Amant F., von Minckwitz G., Han S.N. i wsp.: Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J. Clin. Oncol. 2013; 31: 2532–2539.
  • 6. Mathelin C., Annane K., Treisser A. i wsp.: Pregnancy and post-partum breast cancer: a prospective study. Anticancer Res. 2008; 28: 2447–2452.
  • 7. Johansson A.L., Andersson T.M., Hsieh C.C. i wsp.: Increased mortality in women with breast cancer detected during pregnancy and different periods postpartum. Cancer Epidemiol. Biomarkers Prev. 2011; 20: 1865–1872.
  • 8. Azim H.A. Jr, Santoro L., Russell-Edu W. i wsp.: Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies. Cancer Treat. Rev. 2012; 38: 834–842.
  • 9. Loibl S., von Minckwitz G., Gwyn K. i wsp.: Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer 2006; 106: 237–246.
  • 10. Nicklas A.H., Baker M.E.: Imaging strategies in the pregnant cancer patient. Semin. Oncol. 2000; 27: 623–632.
  • 11. Mazonakis M., Varveris H., Damilakis J. i wsp.: Radiation dose to conceptus resulting from tangential breast irradiation. Int. J. Radiat. Oncol. Biol. Phys. 2003; 55: 386–391.
  • 12. Yang W.T., Dryden M.J., Gwyn K. i wsp.: Imaging of breast cancer diagnosed and treated with chemotherapy during pregnancy. Radiology 2006; 239: 52–60.
  • 13. Novak Z., Thurmond A.S., Ross P.L. i wsp.: Gadolinium- DTPA transplacental transfer and distribution in fetal tissue in rabbits. Invest. Radiol. 1993; 28: 828–830.
  • 14. Birchard K.R., Brown M.A., Hyslop W.B. i wsp.: MRI of acute abdominal and pelvic pain in pregnant patients. Am. J. Roentgenol. 2005; 184: 452–458.
  • 15. Webb J.A., Thomsen H.S., Morcos S.K.; Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR): The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur. Radiol. 2005; 15: 1234–1240.
  • 16. Schackmuth E.M., Harlow C.L., Norton L.W.: Milk fistula: a complication after core breast biopsy. Am. J. Roentgenol. 1993; 161: 961–962.
  • 17. Dominici L.S., Kuerer H.M., Babiera G. i wsp.: Wound complications from surgery in pregnancy-associated breast cancer (PABC). Breast Dis. 2010; 31: 1–5.
  • 18. Goldhirsch A., Winer E.P., Coates A.S. i wsp.; Panel members: Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol. 2013; 24: 2206–2223.
  • 19. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology. Breast Cancer: Version 1.2014. Adres: www.nccn.com.
  • 20. Amant F., Loibl S., Neven P., Van Calsteren K.: Breast cancer in pregnancy. Lancet 2012; 379: 570–579.
  • 21. Rovera F., Frattini F., Coglitore A. i wsp.: Breast cancer in pregnancy. Breast J. 2010; 16: S22–S25.
  • 22. Navrozoglou I., Vrekoussis T., Kontostolis E. i wsp.: Breast cancer during pregnancy: a mini-review. Eur. J. Surg. Oncol. 2008; 34: 837–843.
  • 23. Vinatier E., Merlot B., Poncelet E. i wsp.: Breast cancer during pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol. 2009; 147: 9–14.
  • 24. Amant F., Deckers S., Van Calsteren K. i wsp.: Breast cancer in pregnancy: recommendations of an international consensus meeting. Eur. J. Cancer 2010; 46: 3158–3168.
  • 25. Keleher A., Wendt R. 3rd, Delpassand E. i wsp.: The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid. Breast J. 2004; 10: 492–495.
  • 26. Montgomery L.L., Thorne A.C., Van Zee K.J. i wsp.: Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. Anesth. Analg. 2002; 95: 385–388.
  • 27. Raut C.P., Hunt K.K., Akins J.S. i wsp.: Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a surgical prospective clinical practice protocol. Cancer 2005; 104: 692–699.
  • 28. Cardonick E., Dougherty R., Grana G. i wsp.: Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J. 2010; 16: 76–82.
  • 29. Martin D.D.: Review of radiation therapy in the pregnant cancer patient. Clin. Obstet. Gynecol. 2011; 54: 591–601.
  • 30. Streffer C., Shore R., Konermann G. i wsp.: Biological effects after prenatal irradiation (embryo, foetus). A report of the International Commission on Radiological Protection. Ann. ICRP 2003; 33: 205–206.
  • 31. Galimberti V., Ciocca M., Leonardi M.C. i wsp.: Is electron beam intraoperative radiotherapy (ELIOT) safe in pregnant women with early breast cancer? In vivo dosimetry to assess fetal dose. Ann. Surg. Oncol. 2009; 16: 100–105.
  • 32. Ring A.E., Smith I.E., Jones A. i wsp.: Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J. Clin. Oncol. 2005; 23: 4192–4197.
  • 33. Hahn K.M., Johnson P.H., Gordon N. i wsp.: Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 2006; 107: 1219–1226.
  • 34. Elledge R.M., Ciocca D.R., Langone G., McGuire W.L.: Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients. Cancer 1993; 71: 2499–2506.
  • 35. Azim H.A. Jr, Del Mastro L., Scarfone G., Peccatori F.A.: Treatment of breast cancer during pregnancy: regimen selection, pregnancy monitoring and more… Breast 2011; 20: 1–6.
  • 36. Azim H.A. Jr, Peccatori F.A., Pavlidis N.: Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors. Cancer Treat. Rev. 2010; 36: 101–109.
  • 37. Mir O., Berveiller P., Rouzier R. i wsp.: Chemotherapy for breast cancer during pregnancy: is epirubicin safe? Ann. Oncol. 2008; 19: 1814–1815.
  • 38. Van Calsteren K., Heyns L., DeSmet F. i wsp.: Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J. Clin. Oncol. 2010; 28: 683–689.
  • 39. Zagouri F., Sergentanis T.N., Chrysikos D. i wsp.: Taxanes for breast cancer during pregnancy: a systematic review. Clin. Breast Cancer 2013; 13: 16–23.
  • 40. Mir O., Berveiller P., Goffinet F. i wsp.: Taxanes for breast cancer during pregnancy: a systematic review. Ann. Oncol. 2010; 21: 425–426.
  • 41. Zagouri F., Psaltopoulou T., Dimitrakakis C. i wsp.: Challenges in managing breast cancer during pregnancy. J. Thorac. Dis. 2013; 5 supl. 1: S62–S67.
  • 42. Berveiller P., Mir O.: Taxanes during pregnancy: probably safe, but still to be optimized. Oncology 2012; 83: 239–240.
  • 43. Azim H.A. Jr, Azim H., Peccatori F.A.: Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Rev. Clin. Immunol. 2010; 6: 821–826.
  • 44. Zagouri F., Sergentanis T.N., Chrysikos D. i wsp.: Trastuzumab administration during pregnancy: a systematic review and meta-analysis. Breast Cancer Res. Treat. 2013; 137: 349–357.
  • 45. Goodyer M.J., Ismail J.R., O’Reilly S.P. i wsp.: Safety of trastuzumab (Herceptin) during pregnancy: two case reports. Cases J. 2009; 2: 9329.
  • 46. Waterston A.M., Graham J.: Effect of adjuvant trastuzumab on pregnancy. J. Clin. Oncol. 2006; 24: 321–322.
  • 47. Azim H.A. Jr, Peccatori F.A., Liptrott S.J. i wsp.: Breast cancer and pregnancy: how safe is trastuzumab? Nat. Rev. Clin. Oncol. 2009; 6: 367–370.
  • 48. Pentsuk N., van der Laan J.W.: An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res. B. Dev. Reprod. Toxicol. 2009; 86: 328–344.
  • 49. Abusief M.E., Missmer S.A., Ginsburg E.S. i wsp.: The effects of paclitaxel, dose density, and trastuzumab on treatment- related amenorrhea in premenopausal women with breast cancer. Cancer 2010; 116: 791–798.
  • 50. Azim H.A. Jr, Metzger-Filho O., de Azambuja E. i wsp.: Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). Breast Cancer Res. Treat. 2012; 133: 387–391.
  • 51. Kelly H., Graham M., Humes E. i wsp.: Delivery of a healthy baby after first-trimester maternal exposure to lapatinib. Clin. Breast Cancer 2006; 7: 339–341.
  • 52. Tewari K., Bonebrake R.G., Asrat T., Shanberg A.M.: Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet 1997; 350: 183.
  • 53. Isaacs R.J., Hunter W., Clark K.: Tamoxifen as systemic treatment of advanced breast cancer during pregnancy – case report and literature review. Gynecol. Oncol. 2001; 80: 405–408.
  • 54. Viswanathan S., Ramaswamy B.: Pregnancy-associated breast cancer. Clin. Obstet. Gynecol. 2011; 54: 546–555.
  • 55. Hahn K.M., Johnson P.H., Gordon N. i wsp.: Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 2006; 107: 1219–1226.
  • 56. Bilgin K., Yaramiş A., Haspolat K. i wsp.: A randomized trial of granulocyte- macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics 2001; 107: 36–41.
  • 57. Schibler K.R., Osborne K.A., Leung L.Y. i wsp.: A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis. Pediatrics 1998; 102: 6–13.
  • 58. Sorosky J.I., Sood A.K., Buekers T.E.: The use of chemotherapeutic agents during pregnancy. Obstet. Gynecol. Clin. North Am. 1997; 24: 591–599.
  • 59. Amant F., Van Calsteren K., Halaska M.J. i wsp.: Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol. 2012; 13: 256–264.
  • 60. Tamaru S., Kikuchi A., Takagi K. i wsp.: Neurodevelopmental outcomes of very low birth weight and extremely low birth weight infants at 18 months of corrected age associated with prenatal risk factors. Early Hum. Dev. 2011; 87: 55–59.
  • 61. Dunn J.S. Jr, Anderson C.D., Brost B.C.: Breast carcinoma metastatic to the placenta. Obstet. Gynecol. 1999; 94: 846.
  • 62. Yu J.H., Kim M.J., Cho H. i wsp.: Breast diseases during pregnancy and lactation. Obstet. Gynecol. Sci. 2013; 56: 143–159.
  • 63. Durodola J.I.: Administration of cyclophosphamide during late pregnancy and early lactation: a case report. J. Natl Med. Assoc. 1979; 71: 165–166.
  • 64. Cardonick E., Usmani A., Ghaffar S.: Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry. Am. J. Clin. Oncol. 2010; 33: 221–228.
  • 65. Daneman R., Zhou L., Kebede A.A., Barres BA.: Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 2010; 468: 562–566.
  • 66. Virgintino D., Errede M., Girolamo F. i wsp.: Fetal bloodbrain barrier P-glycoprotein contributes to brain protection during human development. J. Neuropathol. Exp. Neurol. 2008; 67: 50–61.
  • 67. Saunders N.R., Knott G.W., Dziegielewska K.M.: Barriers in the immature brain. Cell. Mol. Neurobiol. 2000; 20: 29–40.
Document Type
communication
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-80c99bb9-7f27-42d1-a1a2-d371883e28db
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.